[A clinical study of the optimal administration method for an immunopotentiator after radiation therapy of malignant tumors].
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*; D011379:Prognosis; D011509:Proteoglycans / Q000008:administration & dosage*; D002583:Uterine Cervical Neoplasms / Q000401:mortality / Q000532:radiotherapy / Q000628:therapy*
D000276:Adjuvants, Immunologic; D011509:Proteoglycans; C010770:polysaccharide-K